Search
Corcept Therapeutics Inc
CORTAdd to Watchlist
116.795USD
+0.565+0.49%
Market hours 10/05, 09:43（ET）
12.63BMarket Cap
255.02P/E TTM
Corcept Therapeutics Inc (CORT) Stock Price Target & Forecast
Analyst Rating
Based on 6 analysts giving stock ratings to Corcept Therapeutics Inc in the past month.
Buy
1 Strong Buy
4 Buy
0 Hold
0 Sell
1 Strong Sell
Target Price
138.787USD+19.41%
CORT Analyst Recommendation Trends
In the current month, CORT has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CORT average Analyst price target in the last month is 138.787.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
1
1
0
0
0
0
0
0
4
4
5
5
4
4
4
4
0
0
1
1
2
2
1
1
1
1
0
0
0
0
1
1
0
0
0
0
0
0
0
0
6
6
6
6
6
6
6
6
CORT Analyst Rating for Peer Comparison
Updated: Oct 4, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Biogen Inc
BIIB
8
16
12
1
0
37
Amgen Inc
AMGN
4
12
18
2
1
37
AbbVie Inc
ABBV
8
19
6
0
0
33
Vertex Pharmaceuticals Inc
VRTX
10
17
5
0
1
33
Merck & Co Inc
MRK
8
14
10
0
0
32
Eli Lilly and Co
LLY
10
18
3
1
0
32
Gilead Sciences Inc
GILD
7
18
6
0
0
31
Neurocrine Biosciences Inc
NBIX
13
14
4
0
0
31
Alnylam Pharmaceuticals Inc
ALNY
5
18
7
0
0
30
Regeneron Pharmaceuticals Inc
REGN
6
14
10
0
0
30
Financial Forecasting
Based on analysts' estimates, CORT EPS is projected to reach 0.814 in FY2026Q3, following reported EPS of 0.408 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
0.30
-0.10
0.01
0.81
1.16
Actual
0.23
-0.30
0.41
--
--
Surprise
-21.92%
-214.60%
+8058.80%
--
--
FAQs
What is Corcept Therapeutics Inc's expected revenue for the next quarter?
Corcept Therapeutics Inc's expected revenue is 336.37M.
What is Corcept Therapeutics Inc's price target?
Analysts forecast that Corcept Therapeutics Inc's price target is USD 138.79, with the highest forecast at USD 165.00 and the lowest forecast at USD 50.00.
How have Corcept Therapeutics IncCORT's recent earnings per share performed?
The market expectation was USD 0.41, while Corcept Therapeutics IncCORT's earnings per share (EPS) for the previous quarter was USD -0.30. EPS for the next quarter is expected at USD 0.81.
What is the analyst rating for Corcept Therapeutics Inc?
Based on the ratings of Corcept Therapeutics Inc's stock from 6 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.